Yuen J - Search Results

1

A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma.

Yau T, Cheng PN, Chan P, Chan W, Chen L, Yuen J, Pang R, Fan ST, Poon RT. Yau T, et al. Among authors: yuen j. Invest New Drugs. 2013 Feb;31(1):99-107. doi: 10.1007/s10637-012-9807-9. Epub 2012 Mar 17. Invest New Drugs. 2013. PMID: 22426640 Free PMC article. Clinical Trial.

2

Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.

Yau T, Cheng PN, Chan P, Chen L, Yuen J, Pang R, Fan ST, Wheatley DN, Poon RT. Yau T, et al. Among authors: yuen j. Invest New Drugs. 2015 Apr;33(2):496-504. doi: 10.1007/s10637-014-0200-8. Epub 2015 Feb 10. Invest New Drugs. 2015. PMID: 25666409 Clinical Trial.

3

Radiofrequency ablation for subcapsular hepatocellular carcinoma.

Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST. Poon RT, et al. Among authors: yuen j. Ann Surg Oncol. 2004 Mar;11(3):281-9. doi: 10.1245/aso.2004.08.018. Ann Surg Oncol. 2004. PMID: 14993023 Clinical Trial.

4

Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter.

Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST. Poon RT, et al. Among authors: yuen j. Arch Surg. 2004 Mar;139(3):281-7. doi: 10.1001/archsurg.139.3.281. Arch Surg. 2004. PMID: 15006885

5

Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution.

Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST, Wong J. Poon RT, et al. Among authors: yuen j. Ann Surg. 2004 Apr;239(4):441-9. doi: 10.1097/01.sla.0000118565.21298.0a. Ann Surg. 2004. PMID: 15024304 Free PMC article.

6

Radiofrequency ablation for hepatocellular carcinoma and metastatic liver tumors: a comparative study.

Chow DH, Sinn LH, Ng KK, Lam CM, Yuen J, Fan ST, Poon RT. Chow DH, et al. Among authors: yuen j. J Surg Oncol. 2006 Dec 1;94(7):565-71. doi: 10.1002/jso.20674. J Surg Oncol. 2006. PMID: 17048238

7

Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization.

Chok KS, Ng KK, Poon RT, Lam CM, Yuen J, Tso WK, Fan ST. Chok KS, et al. Among authors: yuen j. Arch Surg. 2006 Dec;141(12):1231-6. doi: 10.1001/archsurg.141.12.1231. Arch Surg. 2006. PMID: 17178966

8

High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.

Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. Poon RT, et al. Among authors: yuen j. Ann Surg Oncol. 2007 Jun;14(6):1835-45. doi: 10.1245/s10434-007-9366-z. Epub 2007 Apr 4. Ann Surg Oncol. 2007. PMID: 17406950

9

Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma.

Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Ng KK, et al. Among authors: yuen j. J Gastrointest Surg. 2008 Jan;12(1):183-91. doi: 10.1007/s11605-007-0276-y. Epub 2007 Sep 15. J Gastrointest Surg. 2008. PMID: 17874276

10

Duodenopleural fistula formation after percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma.

Chan FS, Ng KK, Poon RT, Yuen J, Tso WK, Fan ST. Chan FS, et al. Among authors: yuen j. Asian J Surg. 2007 Oct;30(4):278-82. doi: 10.1016/S1015-9584(08)60039-1. Asian J Surg. 2007. PMID: 17962132 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

879 results

Search Page

Filters